Barbara Gayle Duncan, Chief Financial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 1,154 shares at $279.00 ($322K) on 2014-04-14, disclosed to the SEC on 2014-04-15.
Scheduled sale ($322k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| JNCE | SELL | 2018-01-29 | $100K | — | Filing → |
| GNMX | BUY | 2017-10-18 | $150K | — | Filing → |
| ICPT | SELL | 2016-10-05 | $24K | — | Filing → |